Hypera Q2 Profit Rises 15% to US$96 Million
Hypera posted Q2 2026 net profit of R$490 million, up 15%, on net revenue of R$2.34 billion. Margins widened and cash generation covered all capex. 149. The post Hypera Q2 Profit Rises 15% to US$96 Million appeared first on The Rio Times .
Hypera, a Brazilian pharmaceutical company, reported a 15% increase in net profit for the second quarter of 2026, reaching R$490.0 million (US$96.4 million). The profit growth was driven by wider gross margins and disciplined working-capital management, which offset increased marketing and selling expenses. Net revenue grew 8.5% year-on-year to R$2.3367 billion (US$459.7 million), while EBITDA from continuing operations rose 4.1% to R$754.9 million (US$148.5 million).
The company's pharmacy sales increased 7.6% in the quarter, outpacing the market by 1.4 percentage points. Gross margin improved by 1.7 percentage points to 61.8%, reflecting a more profitable product mix weighted towards branded generics and consumer health. Earnings per share from continuing operations reached R$0.70 (US$0.14) for the quarter.
The company's free cash flow was R$637.8 million (US$125.5 million), with net debt at R$7.482 billion (US$1.47 billion) and a debt-to-EBITDA ratio of 2.1 times. Hypera's strong performance highlights the recovery's breadth, with cumulative net revenue and profit reaching R$4.35448 billion (US$856.7 million) and R$837.08 million (US$164.7 million), respectively.
Written by urgent.news from The Rio Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
